What’s Ahead for Ironwood Pharmaceuticals Inc – Class A (NASDAQ:IRWD) After More Shorted Shares?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Logo

Investors sentiment increased to 1.63 in Q2 2019. Its up 0.26, from 1.37 in 2019Q1. It increased, as 20 investors sold Ironwood Pharmaceuticals, Inc. shares while 26 reduced holdings. 21 funds opened positions while 54 raised stakes. 149.39 million shares or 1.83% more from 146.70 million shares in 2019Q1 were reported.
Prudential Fincl invested in 0% or 14,124 shares. Shell Asset Company has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Royal Commercial Bank Of Canada stated it has 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Employees Retirement Association Of Colorado owns 24,883 shares or 0% of their US portfolio. Tocqueville Asset L P owns 28,531 shares. Ecor1 Capital owns 4.67M shares or 5.16% of their US portfolio. 13D Management Limited Liability Corporation owns 489,530 shares for 1.61% of their portfolio. Barclays Public Lc reported 149,028 shares stake. Amer Century Companies owns 289,701 shares. California Public Employees Retirement System owns 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 230,106 shares. 1.79M were accumulated by Northern Trust Corp. 525,400 are owned by Opaleye Mngmt Incorporated. 4.15M are held by Citadel Advisors Limited Liability Company. Fosun Ltd has invested 0.31% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Tower Research Lc (Trc) accumulated 0% or 185 shares.

The stock of Ironwood Pharmaceuticals Inc – Class A (NASDAQ:IRWD) registered an increase of 4.04% in short interest. IRWD’s total short interest was 17.70 million shares in September as published by FINRA. Its up 4.04% from 17.01M shares, reported previously. With 1.39M shares average volume, it will take short sellers 13 days to cover their IRWD’s short positions.

The stock decreased 0.52% or $0.05 during the last trading session, reaching $9.6. About 2.04M shares traded or 10.83% up from the average. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 32.56% since September 13, 2018 and is downtrending. It has underperformed by 32.56% the S&P500.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $1.50 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 3 analysts covering Ironwood Pharma (NASDAQ:IRWD), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Ironwood Pharma has $16 highest and $13 lowest target. $14.33’s average target is 49.27% above currents $9.6 stock price. Ironwood Pharma had 5 analyst reports since March 22, 2019 according to SRatingsIntel. Morgan Stanley upgraded the stock to “Equal-Weight” rating in Wednesday, March 27 report. The firm has “Hold” rating by Credit Suisse given on Friday, March 22. H.C. Wainwright maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Monday, June 24. H.C. Wainwright has “Hold” rating and $13 target.

More notable recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Nasdaq.com which released: “Ardelyx (ARDX) Gains on Tenapanor’s Success in Pivotal Study – Nasdaq” on September 04, 2019, also Finance.Yahoo.com with their article: “Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ? – Yahoo Finance” published on May 02, 2019, Seekingalpha.com published: “Ironwood Pharmaceuticals misses by $0.03, misses on revenue – Seeking Alpha” on May 02, 2019. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were released by: Nasdaq.com and their article: “Investors Can Find Big Returns with this First Profit Screen – Nasdaq” published on September 10, 2019 as well as Finance.Yahoo.com‘s news article titled: “Ironwood Pharmaceuticals’ Blowout Q2 Results: What You’ll Want to Know – Yahoo Finance” with publication date: July 31, 2019.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.